This company has been marked as potentially delisted and may not be actively trading. Affimed (AFMD) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesOwnershipShort InterestSustainabilityTrendsBuy This Stock Get the Latest News and Ratings for AFMD and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Affimed and its competitors. Enter your email to sign up for newsletter Sign Up AFMD Analyst Ratings Over TimeTypeCurrent Forecast7/15/24 to 7/15/251 Month Ago6/15/24 to 6/15/253 Months Ago4/16/24 to 4/16/251 Year Ago7/16/23 to 7/15/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy0 Buy rating(s)0 Buy rating(s)4 Buy rating(s)6 Buy rating(s)Hold6 Hold rating(s)6 Hold rating(s)1 Hold rating(s)0 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$3.62$3.62$13.50$41.67Forecasted Upside1,895.87% Upside1,895.87% Upside1,759.50% Upside716.99% UpsideConsensus RatingHoldHoldModerate BuyBuy AFMD Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History AFMD Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Affimed Stock vs. The CompetitionTypeAffimedMedical CompaniesS&P 500Consensus Rating Score 2.00 2.81 2.53Consensus RatingHoldModerate BuyModerate BuyPredicted Upside1,895.87% Upside9,034.04% Upside12.42% UpsideNews Sentiment RatingNeutral NewsSee Recent AFMD NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails5/14/2025Cantor Fitzgerald3 of 5 starsL. WatsekSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/14/2025HC Wainwright1 of 5 starsSwayampakula RamakanthSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/13/2025Leerink Partnrs1 of 5 starsD. GrayboschSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/13/2025Wells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingYanan ZhuSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$11.00 ➝ $0.10-25.37%5/13/2025Leerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDaina GrayboschSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$5.00 ➝ $0.39-43.72%11/15/2024Stifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetHold ➝ Hold$5.00 ➝ $4.00+9.59%6/13/2024LaidlawSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetBuy$15.00 ➝ $25.00+252.11%8/11/2023Truist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetBuy ➝ Buy$80.00 ➝ $60.00+1,003.95%8/8/2023Berenberg BankSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingBuy$60.00+971.43%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 11:06 PM ET. AFMD Forecast - Frequently Asked Questions What is Affimed's forecast for 2025? According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Affimed is $3.62, with a high forecast of $10.00 and a low forecast of $0.10. Should I buy or sell Affimed stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last twelve months. There are currently 6 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AFMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AFMD, but not buy additional shares or sell existing shares. Does Affimed's stock price have much upside? According to analysts, Affimed's stock has a predicted upside of 1,895.87% based on their 12-month stock forecasts. Has Affimed been downgraded by Wall Street analysts recently? Over the previous 90 days, Affimed's stock had 3 downgrades by analysts. What analysts cover Affimed? Affimed has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, Leerink Partners, Leerink Partnrs, and Wells Fargo & Company in the past 90 days. Do Wall Street analysts like Affimed more than its competitors? Analysts like Affimed less than other "medical" companies. The consensus rating for Affimed is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AFMD compares to other companies. Stock Forecasts and Research Tools Related Companies Minerva Neurosciences Stock Forecast Phio Pharmaceuticals Stock Forecast Equillium Stock Forecast Abpro Stock Forecast Brainstorm Cell Therapeutics Stock Forecast Sensei Biotherapeutics Stock Forecast Acurx Pharmaceuticals Stock Forecast BioCardia Stock Forecast X4 Pharmaceuticals Stock Forecast GlycoMimetics Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:AFMD) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Share Affimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
